Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Uncle Avtar!
Unfortunatly this CEO does not have a poly-science degree but an actual MD and MBA from MIT!
Curam grant PR
In addition to receiving infrastructure support, for each €1 up to an annual maximum of €250,000 that Arch contributes to its own R&D activities within CÚRAM, CÚRAM will contribute €2 up to an annual maximum of €500,000 to those same activities, made possible by its grant funding from Science Foundation Ireland (SFI).
Science wise this stock looks great. Approval proces is a lot quicker since it is considered a medical device.
However their major issue is cash. They keep changing warrants wich makes it difficult to keep track.
Curam grant was rather dissapointing
sorry but I presented the evidence yesterday. Newbies and savvy investors alike have taken notice
1) validation of concept
2) statistically significant
Probably Vallejogzte was sitting tight on cash and told Punit he can only fo mini/trials.
Lets hope the nex CFO tells him to ho wild and fo 500 patient trails.
It is there, go look
But hen again, i will not do your DD
I got trampled by the herd on their way to dump Oncosec
Should have listened to thr savvy investors who said it for months
Well dont jump to conclusions. Maybe she has frauded the quarterly reports and has Zacks uncovered it with some Pullitzer investigational research. Now who could be Deep Throat?
hey another gate
I propose we go for Oncogate. Any savvy investor can see that we are all scammed for our money
Luckiliy we have Zacks saving us from going bust
I have given you the info, go look back
but for the future sales value in biotech sector, you do not look to the next quarter
Zacks looks to the next quarter or 6 months only.
It is not rockectscience.
Ah I got you confused there. Sorry for that.
Let me help it to make it more clearer for you:
Zack uses current estimates. Which of course for any biotech (ONCS included) is negative as they have no revenue from the sales of commercial products.
When one wants to calculate possible future share price, one uses the sales potential of a product.
I guess since both are called estimate, that got you confused.
Hope I made it clearer for you now.
But as I am nice cooperative person:
Zacks and the Zacks Rank
In 1978, Zacks Investment Research was formed to compile and analyze brokerage research for both institutional and individual investors.
Zakcs rank
Today, Zacks processes this information from roughly 3,000 analysts at over 150 different brokerage firms. At any given point in time, we're monitoring well over 200,000 earnings estimates and other related data looking for any change. Our ability to gather, analyze and distribute this information on a timely basis makes Zacks' research among the most widely used investment research on the web.
Len Zacks and the Creation of the Zacks Rank
The Zacks Rank was created by Leonard Zacks, the CEO and founder of Zacks Investment Research. Len, who has a PhD from MIT, spent many years on Wall Street testing statistical models to help uncover ways to beat the market. This research led to the breakthrough discovery:
Earnings estimate revisions are the most
powerful force impacting stock prices
-Len Zacks
His findings were first published in 1979 in the Financial Analysts Journal and entitled "EPS Forecasts -- Accuracy Is Not Enough". From this seminal work emerged the now famous Zacks Rank stock picking system, which harnesses the power of earnings estimate revisions. And so began a long tradition of innovation by his renowned firm, Zacks Investment Research.
The Zacks Rank uses four factors related to earnings estimates to classify stocks into five groups, ranging from Strong Buy to Strong Sell. More importantly, it allows individual investors to take advantage of trends in earnings estimate revisions, and benefit from the power of institutional investors.
I do not need any facts, I am a member at Zacks so I know how they operate.
Believe me when I tell you that the whole Zakcs concept is based on earnings estimates.
That works great with established companies but not with biotech without a commercial product.
read my words please, I said "any source that bashes"
I am speaking in generalities
But you fail to notice one of my previous post were I tried to explain that Zacks works on earnings estimates, not on science. In case of ONCS they have probably based their rating on the fact that the burnrate has increase, and likely as well that ONCS was unwilling to pay them.
you find Zacks a trustworthy source?
All of their recommendation are based on earnings estimates and none on science. Their recommendations regarding biotech are not evening worth the paper printed on because all biotech have negative estimates prior a commercial product.
So yeah it means pretty munch nothing.
don't you worry sharpei, we are used to a lot worse!
Expect a pr on Tuesday
Zacks works only based on quarterly results. Meaning that ther whole coverage of biotech startups is worth zero. The Zacks rank is okay for mature companies who actually sell something.
I propose we wait and see how the results turn out. Too premature at the moment.
Thats an interesting hypothesis you make here Inv. It makes sense to hire somebody with his experience level.
Factually wrong: closed down 0,16$ lower or -2.27%
Yeah ever since we went up to Nasdaq, the volume has increased significantly
i.m trying the mental picture... not nice ;)
Pritty lame to refer to Kirk as a nobody. Is Buffet a pimpel too?
Oh yeah of course, today would be day 7 above 1$
We need the next series of warrants to be exercised.
Data will speak so much louder then a SA article
I think this is very healthy for the stock after such a sprint upwards.
Cool down, settle and then start the next race.
What explanation are you expecting here to give when she resigns?
For all we know there are family related issues and she has to re-orientate here priorities. One would not expect to read this in a PR.
So know a speculation has become a hard fact.
I will state it again for all newbies who could be at risk of taking speculation for truth: CFO has resigned. There is zero evidence to show that she has been pushed out.
It's a simple question. Please provide evidence that she was pushed out instead of resigning, as the PR says
Wait, I reacted on the part were you say ONCS failed to sent out a PR.
I am expecting that one tomorrow.
I am not claiming anything. The PR says she has resigned
It;s up to you to support the interpretation that the CFO has been pushed out
Wait wait, they join on 26th
Today is still 25th
LOL, you have humor
I am not claiming anything.
The statement says she has resigned
speculation, at best
quote:
Veronica Vallejo, the current Chief Financial Officer of OncoSec, resigned from her position effective June 24, 2015 to pursue other opportunities.
Obviously a coordinated move as they announce the replacement in one go.
it's for animals
New CFO announced
Veronica Vallejo has resigned to pursue other activities. New CFO has 25 years financial executive experience in life science and technology companies.
I hope he is a nice guy too!
Typical pattern shows that big boys are accumulating
Volule precedes price
It's called the Nasdaq effect